Varenicline Tablet, Film Coated
Product Images NDC 50090-8088

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Varenicline (NDC 50090-8088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500908088)

Varenicline 0.5 mg film-coated tablets in a bottle label marked with NDC 50090-8088, distributed by A-S Medication Solutions. The label states each film-coated tablet contains 0.85 mg varenicline tartrate equivalent to 0.5 mg varenicline free base. The bottle contains 56 tablets and includes storage instructions to store at 68 to 77 degrees Fahrenheit.*

FDA Label Image

222 (Varenicline Tab Fig 1)

A bar chart titled 'Continuous Abstinence, Weeks 9 through 12' comparing the percentage of continuous abstinence among different treatment groups across five studies. The chart displays data for Varenicline tablets at 0.5 mg and 1.0 mg dosages, b.i.d. (twice daily), varenicline SR tablets at 1.0 mg, and placebo groups, showing variations in abstinence rates for each study.*

FDA Label Image

333 (Varenicline Tab Fig 2)

A bar chart titled 'Continuous Abstinence, Weeks 9 through 52' comparing the percent abstinence rates across five studies. The treatments compared include Varenicline Tablets 1 mg BID, Varenicline Tablets 0.5 mg BID, Placebo, and Varenicline Tablets SR 0.5 mg BID, presented with error bars representing variability. Differences in abstinence rates are shown visually among these groups for studies labeled 2 through 5.*

FDA Label Image

444 (Varenicline Tab Fig 3)

A line graph titled 'Continuous Abstinence Rate during Nontreatment Follow-Up' depicting the percentage of continuous abstinent individuals over weeks of nontreatment follow-up. The graph compares Varenicline Tablets 1.0 mg twice daily (BID) and placebo groups, showing higher abstinence rates for the Varenicline group across the follow-up period.*

FDA Label Image

111 (Varenicline Tab Structure)

Chemical structure of varenicline, the active ingredient shown in the image, depicting the atomic connectivity and ring formations characteristic of its molecular structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.